The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: Clinical trial evidence and experience

Therapeutic Advances in Neurological Disorders

Volumn 8, Issue 3, 2015, Pages 137-147

  Steinhoff, Bernhard J ^a  

^a Epilepsy Centre Kork   (Germany)

Author keywords

drug therapy; epilepsy; glutamate; perampanel

Indexed keywords

AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETIRACETAM; KETOCONAZOLE; LAMOTRIGINE; OXCARBAZEPINE; PERAMPANEL; PHENOBARBITAL; PHENYTOIN; PLACEBO; RUFINAMIDE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ASTHENIA; ATAXIA; BALANCE DISORDER; CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; EPILEPSY; EPILEPTIC STATE; EVENING DOSAGE; FATIGUE; FOCAL EPILEPSY; GAIT DISORDER; HEADACHE; HUMAN; INSOMNIA; MEMORY DISORDER; MENTAL DISEASE; MESIAL TEMPORAL LOBE EPILEPSY; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SEIZURE; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION;

EID: 84930407191     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285615575696     Document Type: Review

References (31)

1. Bialer M. Johannessen S. Levy R. Perucca E. Tomson T. White H. (2010) Progress report on new antiepileptic drugs: a summary of the Tenth EILAT Conference (EILAT X). Epilepsy Res 92: 89–124.
2. Brodie M. Covanis A. Gil-Nagel A. Lerche H. Perucca E. Sills G. et al. (2011) Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav 21: 331–341.
3. Chappell A. Sander J. Brodie M. Chadwick D. Lledo A. Zhang D. et al. (2002) A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 58: 1680–1682.
4. Coyle H. Clough P. Cooper P. Mohanraj R. (2014) Clinical experience with perampanel: focus on psychiatric adverse events. Epilepsy Behav 41: 193–196.
5. Faught E. (2014) BGG 492 (selurampanel), an AMPA / kainate receptor antagonist drug for epilepsy. Expert Opin Investig Drugs 23: 107–113.
6. French J. Krauss G. Biton V. Squillacote D. Yang H. Laurenza A. et al. (2012) Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 79: 589–596.
7. French J. Krauss G. Steinhoff B. Squillacote D. Yang H. Kumar D. et al. (2013) Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305. Epilepsia 54: 117–125.
8. Hanada T. Hashizume Y. Tokuhara N. Takenaka O. Kohmura N. Ogasawara A. et al. (2011) Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 52: 1331–1340.
9. Hsu W. Sing C. He Y. Worsley A. Wong I. Chan E. (2013) Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy. CNS Drugs 27: 817–827.
10. Kramer L. Satlin A. Krauss G. French J. Perucca E. Ben-Menachem E. et al. (2014) Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose–response analysis of phase-III trials. Epilepsia 55: 423–431.
11. Krauss G. Bar M. Biton V. Klapper J. Rektor I. Vaiciene-Magistris N. et al. (2012) Tolerability and safety of perampanel: two randomized dose-escalation trials. Acta Neurol Scand 125: 8–15.
12. Krauss G. Perucca E. Ben-Menachem E. Kwan P. Shih J. Clément J. et al. (2014) Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia 55: 1058–1068.
13. Krauss G. Perucca E. Ben-Menachem E. Kwan P. Shih J. Squillacote D. et al. (2013) Perampanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, open-label extension study 307. Epilepsia 54: 126–134.
14. Krauss G. Serratosa J. Villanueva V. Endziniene M. Hong Z. French J. et al. (2012 b) Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 78: 1408–1415.
15. Löscher W. (2002) Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res 50: 105–123.
16. Löscher W. (2011) Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 20: 359–368.
17. Meldrum B. Rogawski M. (2007) Molecular targets for antiepileptic drug treatment. Neurotherapeutics 4: 18–61.
18. Novy J. Rothuizen L. Buclin T. Rossetti A. (2014) Perampanel: a significant liver enzyme inducer in some patients? Eur Neurol 72: 213–216.
19. Patsalos P. (2014) The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia. DOI: 10.1111/epi.12865.
20. Prescrire New Products (2014) Perampanel. Just another anticonvulsant for partial epilepsy: no progress. Prescrire Int 23: 179.
21. Rogawski M. (2011) Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 11: 56–63.
22. Schmidt D. Schachter S. (2014) Drug treatment of epilepsy in adults. BMJ 348: g254.
23. Steinhoff B. (2013) Anticonvulsant drug therapy of adolescents and adults. State of the art. Z Epileptol 26: 142–153.
24. Steinhoff B. (2014 a) Introduction: perampanel – new mode of action and new option for patients with epilepsy. Epilepsia 55(Suppl. 1): 1–2.
25. Steinhoff B. (2014 b) Efficacy and tolerability of the new antiepileptic drug perampanel – trial data and clinical experience. Med Men Geist Mehrf Beh 11: 11–22.
26. Steinhoff B. Bacher M. Bast T. Kornmeier R. Kurth C. Scholly J. et al. (2014 a) First clinical experiences with perampanel – the Kork experience in 74 patients. Epilepsia 55(Suppl. 1):16–18.
27. Steinhoff B. Ben-Menachem E. Ryvlin P. Shorvon S. Kramer L. Satlin A. et al. (2013) Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies. Epilepsia 54: 1481–1489.
28. Steinhoff B. Hamer H. Trinka E. Schulze-Bonhage A. Bien C. Mayer T. et al. (2014 b) A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria. Epilepsy Res 108: 986–988.
29. Steinhoff B. Laurenza A. Yang H. Satlin A. (2014 c) Safety profile of perampanel as an adjunctive treatment for partial-onset seizures. J Sympt Signs 3: 64–70.
30. Vollmar W. Gloger J. Berger E. (2004) RNA editing (R/G site) and flip-flop splicing of the AMPA receptor subunit GluR 2 in nervous tissue of epilepsy patients. Neurobiol Dis 15: 371–379.
31. Zilles K. Qu M. Köhling R. Speckmann E. (1999) Ionotropic glutamate and GABA receptors in human epileptic tissue: quantitative in vitro receptor autoradiography. Neuroscience 94: 1051–1061.